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Abstract
Background: The production and consumption of cannabis for the treatment of medical conditions
is of increasing importance internationally; however, research on different aspects of the 
phenomenon is still scarce. In this article, we report findings from a cross-cultural study of small-
scale cannabis cultivation for medical purposes. This kind of comparative study has not been done 
previously.
Methods: The data were gathered with a help of web surveys conducted by the Global Cannabis 
Cultivation Research Consortium (GCCRC) in Australia, Belgium, Denmark, Finland, Germany and 
the UK (N=5,313). In the analysis we compare reports of medical motives, for what conditions 
cannabis is used, whether users have diagnoses for these conditions and whether the use of 
cannabis been recommended as a treatment of those conditions by a medical doctor. Descriptive 
statistics are used to show the main commonalities and noteworthy disparities across different 
countries.
Results: Findings from countries were quite similar, even though several national differences in 
details were found. Growing cannabis for medical purposes was widespread. The majority of 
medical growers reported cultivating cannabis for serious conditions. Most of them did have a 
formal diagnosis. One fifth had got a recommendation from their doctor, but in most cases 
cannabis use was self-medication which was not discussed with their doctors.
Conclusion: There is a wider demand for licit access for medical cannabis than currently available 
in these countries. Ideologically, medical growers can be seen distancing themselves from both the 
legal and illicit drug markets. From a harm reduction perspective, it is worrying that, in the context 
of present health and control policies in these countries, many medical growers are using cannabis 
to treat serious medical conditions without proper medical advice and doctor’s guidance.













The interest in medical cannabis, i.e. use of cannabis for therapeutic purposes, has increased 
immensely since the early 1990s. Four factors have triggered this development. Firstly, a social 
movement has developed which has fought for legal access to medical cannabis. This movement 
has been most visible and powerful in the USA (Geluardi, 2010; Dyer, 2013) but also appeared in 
some other countries like Canada (Penn, 2014) and Germany (Grotenhermen, 2002). Secondly, 
the pressure created by the medical cannabis advocacy has led to changes in official policy. In 
California, USA, the passing of Proposition 215 legalized medical marijuana in 1996, and 
subsequently many other states have decided to follow the Californian example (Geluardi, 2010). 
Thirdly, the growing significance of medical cannabis has garnered interest from the 
pharmaceutical industry which has been developing alternative products to herbal cannabis: e.g. 
since the mid-1980s synthetic THC (dronabinol, marketed as Marinol®) has been available and 
since 2004; Sativex®, a plant-based extract has become a registered pharmaceutical product in a 
number of countries. Also, the state authorities are involved in many ways in the production of 
medical cannabis (e.g. Crawford, 2013). Fourthly, a growing body of research on the therapeutic 
value of cannabis has been published (e.g. AMA, 2009; CMCR, 2010; Grant, Atkinson, Gouaux, & 
Wilsey, 2012; Kalant & Porath-Waller, 2012; Borgelt, Franson, Nussbaum, & Wang, 2013). Even 
though the topic is controversial, support for the use of cannabis for medical purposes might be 
increasing among clinicians internationally as shown in the recent Clinical Decision of the New 
England Journal of Medicine (Adler, & Colbert, 2013). In short, we are experiencing a formative 
period in policy and practice around medical cannabis.
The increased interest in medical cannabis can be seen as a revival of historic use of cannabis for 
medical purposes. Indeed, the use of cannabis and cannabis-based preparations for therapeutic 
purposes has a long history and has been known in many cultures all over the world (Aldrich, 
1997; Grinspoon & Balakar, 1997; Russo, 2007). In the West, cannabis did not play any significant 
role until the 19th century when it became a popular ingredient in medicines and commercial 












preparations in Europe and the United States. However, by the end of the century, cannabis was 
already falling out of favour and it was replaced by new synthetic pharmaceuticals such as aspirin 
and barbiturates (Fankhauser, 2008). Furthermore, as cannabis was included under the 
international narcotics control system and classified in Schedule I of the Single Convention in 
1961, it was described as having only a limited medical value, but a high potential for abuse. This 
scheduling frames discussion about medical cannabis even today.
In fact, the renewed interest in medical cannabis is hotly debated. Physicians, health authorities 
and politicians still ask for more evidence before recognizing cannabis as an approved treatment.
At the same time, there is much resistance towards legalizing cannabis for medical purposes by 
state powers, since they are concerned that a creation of a category of licit (medicinal) cannabis 
use would blur the boundaries between illegal and legal drugs and thereby challenge the ideology 
of prohibition in drug policy. Consequently, with the exception of some US states, in most countries 
where medical cannabis has been made formally available, it has often been implemented under a 
strictly regulated system where a patient needs a recommendation from a specialized doctor and 
the variety of the available products is strongly limited. Moreover, in practice physicians in health 
care might be sceptical and reluctant to suggest medical cannabis for their patients 
(Grotenhermen, 2002; Dahl & Frank, 2011; Pedersen & Sandberg, 2013). Further, there are also 
concerns about smoking as a mode of administration.  Whilst delivery systems such as 
vaporization remain a possibility, it is extremely unlikely in many countries that a product that is 
smoked will be approved as a medicine.
Furthermore, our understanding of the characteristics and practices of those who use cannabis for 
medical purposes is limited. While there is a growing body of studies of authorized patient 
populations (e.g. Reinarman, Nunberg, Lanthier, & Heddleston, 2012; Walsh et al., 2013) in the 
countries where medical cannabis has become legal, little is known about self-medication and how 
and why individuals define their cannabis use as medical in the countries where access to medical 
cannabis is denied or strongly limited (Ogborne, Smart, Weber, & Birchmore-Timney, 2000; Ware, 












Adams, & Guy, 2005; Dahl & Frank, 2011; Pedersen & Sandberg, 2013). Specifically, our 
understanding of how medical cannabis users cope with legal barriers and restricted access is 
limited. 
One recognised way to deal with a lack of legal access is to turn to home-growing or to rely on 
home-grown cannabis supplies from others. For example, in surveys conducted in Belgium, 
Denmark and Finland on cannabis growing 2 %, 24 % and 59 % of the respondents, res ectively, 
gave ‘medical use’ as a reason for growing (Decorte, 2010; Hakkarainen, Frank, Dahl, & Perälä, 
2011). However, in these studies no further details were available on the underlying medical 
conditions for which the cannabis was being used. This is important since the boundary between 
medical and recreational use of cannabis is contested (Potter, 2010; Dahl & Frank, 2011; 
Hakkarainen, Perälä, & Metso, 2011; Reinarman et al., 2012; Pedersen & Sandberg, 2013).
The present article takes up the challenge of investigating medical cannabis use from the
perspective of those who grow cannabis to supply themselves or others with medicinal cannabis. 
In this contribution we use the terms ‘medical growing’ and ‘medical growers’ to refer to this 
phenomenon. We compare the appearance of medical motives in the samples of cannabis growers 
from six different countries, including the medical conditions for which cannabis is used, , whether 
users have a diagnosis for these conditions, and whether their use of cannabis has been 
recommended as a treatment of those conditions by a doctor. Samples of cannabis growers are 
included from Australia, Belgium, Denmark, Finland, Germany and the UK.
Medical cannabis policy in these six countries has been evolving since the mid-1990s. However, 
while there are differences in how these countries have dealt with medical cannabis, formal laws 
and policies in all six countries were still very similar at the time of writing this article. Some 
pharmaceutical cannabis products like Marinol® and Sativex® are available in all countries except 
Australia. Products of herbal cannabis (e.g. Bedrocan®) are accessible in Finland and Germany
with a special authorization, and there are a few ongoing clinical trials in the UK. In general, access 
to cannabis treatment is strictly regulated and predominantly limited to certain specified medical 












conditions. Furthermore, authorised cannabis treatment seems to be relatively expensive for an 
individual user, especially when health insurance providers do not reimburse the costs 
(Grotenhermen, 2002). It is also apparent that many medical authorities and GPs are reluctant to 
widen access to medical cannabis, especially beyond these limited number of approved 
pharmaceutical products to the consumption of herbal cannabis. In the context of limited access, 
reserved attitudes and expensive costs of the official cannabis medication, the illicit market and a 
supply based on home growing are likely to appear as attractive alternatives (Grinspoon, 2001; 
Grotenhermen, 2002). 
With the exception of industrial hemp and licenced growing for scientific purposes cannabis 
growing is illegal in all six countries. In Belgium, however, a joint guideline issued by the Minister of 
Justice and the College of Public Prosecutors in 2005 sets out that the lowest prosecution priority 
is to be given to the possession by adults of an amount of cannabis suitable for personal use, 
which is to say quantities not exceeding three grams or one cultivated plant (without aggravating 
circumstances or causing disturbance of the public order). In other words, in the case of growing 
not more than one plant, the person concerned will not receive a criminal record. Another 
exception was recently made by Germany: in December 2012 the Federal Administrative Court 
ruled that seriously ill patients may grow their own cannabis for medicinal uses (German medical
marijuana patients allowed to grow their own, 2013). Patients who wish to take part can apply to 
the Federal Institute for Drugs and Medical Devices for permission to treat themselves with 
homegrown cannabis, with use monitored by a medical doctor.
Data for this study stems from national web surveys conducted by the Global Cannabis Cultivation 
Research Consortium (GCCRC). Surveys were designed to compare data on cannabis growers, 
including growing for medical purposes (Barratt et al., 2012). This created an opportunity to study 
and compare whether, and in what ways, growers cultivating cannabis for medical purposes are 
alike in different national contexts. While there are some studies dealing with medical cannabis 












cultivation within a national context (e.g. Hough et al., 2003; Potter, 2010; Dahl & Frank, 2011) this 
kind of comparative study has not been done previously.
Data and methods
Data gathered during 2012-2013 was based on the International Cannabis Cultivation 
Questionnaire (ICCQ) developed by the GCCRC to measure patterns of small-scale cannabis 
cultivation (Decorte et al., 2012). In addition to the questions incorporated in the ICCQ-
questionnaire, individual countries inserted their own items or modules. Detailed questions about 
growing cannabis for medical purposes were an additional module employed by those six countries 
included in this analysis. 
The methodology of the GCCRC study has been described in some depth elsewhere (Barratt et 
al., 2012) and a more detailed report of methods and data can be found in another article in this 
volume (xxxx, this volume). Hence, just a short overview is provided here. A broad-based 
recruitment strategy and techniques to maximise the breadth of recruitment coverage were used. 
However, in practice the mix of strategies varied from country to country, and it became apparent 
that in some countries recruitment of cannabis growers into the study was more challenging than in 
other countries. This can also be seen in the variation of the number of respondents in different 
countries. Consequently, we cannot precisely estimate how comparable the samples from each 
country are to each other. On the other hand, it has been noted that subjects responding web 
surveys are comparable to those responding traditional modes of data collection based on 
volunteering in terms of age, gender, income, and health status (West et al., 2006; van Gelder, 
Bretveld, & Roeleveld, 2010). Furthermore, our recruitment strategies and use of a web-based 
questionnaire has provided us with larger samples of cannabis cultivators than we would have 
been able to recruit using traditional research methods.












Eligibility criteria for inclusion in the analysis were that the respondent had grown cannabis during 
the past five years and had filled at least 50 per cent of the questionnaire. The number of eligible 
respondents across the six countries which asked about medical cannabis totalled 5,313. A fuller 
description of sample characteristics can be found in Potter, Barratt, Malm, Bouchard, Blok et al., 
this volume.
Measurements
In order to measure the prevalence of medical growing the respondents were asked reasons for
growing. The respondents were allowed to select as many answers as relevant for describing their 
motivation for growing from 20 response alternatives (Potter, Barratt, malm, Bouchard, Blok et al., 
this volume). Two of the different response options concerned medical growing. They were (a) “to 
provide others with cannabis for medical reasons”, and (b) “to provide myself with cannabis for 
medical reasons”.
To know for which types of conditions cannabis was used as medicine the respondents were 
offered a list of health problems, typically linked in the literature to medical cannabis, and an open 
field to add other conditions for which they used medical cannabis. 
In order to collect information about the relationship between medical growers and the national 
medical practice questions were included concerning diagnoses and advice given by medical 
doctors. In Australia, Denmark and the UK the question about diagnosis allowed several fixed-
choice response alternatives: (1) medical doctor or medical specialist, (2) other medical 
professional, (3) alternative health practitioner, (4) friend, and (5) self-diagnosed. In the analysis 
only the first category was coded as having a diagnosis whereas other options were reduced into 
the category “not diagnosed by a doctor”. Regarding whether or not the use of cannabis as 
medicine was suggested or recommended by the doctor response options were as follows:
a) Yes, the doctor has suggested or recommended use of cannabis as a medicine 












b) No, the doctor has refused to recommend cannabis use even though I have asked for it 
c) No, the doctor did not suggest or recommend cannabis use and I have not asked for it 
d) No, on the contrary, the doctor advised me to avoid using cannabis 
Options b, c, and d were not asked in Belgium and Germany.
Due to variations in the medical cannabis modules in the six countries, all questions were not 
asked in an identical way. Australia, Denmark and the UK used exactly the same additional 
module, whereas Belgium, Finland and Germany each applied a slightly different version of the 
module. Furthermore, in Australia the additional module was not included until a few weeks after 
the survey had launched, and in Denmark there was a technical glitch in the questionnaire which 
ruled out last two questions for the majority (71 %) of respondents. Therefore, the number of valid 
responses varies in each question. Results are presented so that only comparable information is 
included in tables. Analysis is kept on a descriptive level showing the main commonalities and 
noteworthy disparities across different countries, but we will also point out some more general 
themes for discussion.
Findings
Prevalence of medical growing
The prevalence of medical growing in different country samples is presented in Table 1. The 
category “other reasons” covers respondents who did not report any medical reasons.
Insert table 1 about here












Firstly, as Table 1 suggests, medical reasons were reported by sizeable proportions of the 
cannabis growers recruited in this study. Altogether 45 per cent of all respondents (N=2,346) 
reported providing either themselves or others with cannabis for medical purposes. Some 67 per 
cent of them were providing only themselves, 9 per cent provided only others, and 23 per cent both 
themselves and others. Methodologically, the relatively large number of medical growers in the 
sample creates a reasonable ground for more detailed comparisons.
Secondly, even if growing cannabis for medical purposes seems to be a relatively widespread 
practice among the small-scale cannabis growers in these samples there were also substantial 
differences between country samples. The prevalence of reporting medical growing as a reason for 
growing was highest in Australia, Finland and the UK where a majority of the respondents reported 
that they were growing for medical purposes either providing themselves or others. The samples 
from Denmark and Germany formed another group where proportions of medical growers were 
close to half of the respondents. Appearance of medical growing was clearly lowest in the Belgian
sample.
Altogether 88 per cent of medical growers were males, and there were no significant differences in 
this gender ratio between the countries. The mean age of the total sample of medical growers was 
32.2 years. It was highest in the Australian sample (39.0 years), although the total (medical and 
non-medical growers) Australian sample was older than other countries (see Potter et al, this 
volume), and lowest in the Finnish sample (26.4 years), respectively 32.3 years in Belgium, 33.1 
years in Denmark, 30.9 years in Germany and 35.8 years in in the UK. Differences in mean age 
were statistically significant (Table 2). In comparison to non-medical/recreational growers (mean 
age 29.3) medical growers were somewhat older.
Insert table 2 about here












The five most popular options among the other reasons for growing selected by the medical 
growers were: “it provides me with cannabis for personal use” (89 %); “I get pleasure from growing 
cannabis” (85 %), “to avoid contact with criminals” (85 %); “the cannabis I grow is healthier than 
the cannabis I can buy” (77 %); and ”it’s cheaper than buying cannabis” (75 %). In Germany this 
question also included an option “the cannabis I can grow will never contain adulterants” which 
was chosen as an important motivation by 95 per cent of local medical growers. Hence, in addition 
to personal use, aesthetic motivations and economic austerity medical growers were showing a 
deep distrust of the street marked and criminal networks. This finding corresponds to previous 
literature classifying medical cultivators into the cluster of ideological growers who are clearly 
distinguishable from those growing for financial gain (Potter, 2010). Indeed, only 9 per cent of 
medical growers expressed a selling motivation as a reason of growing, with variation between 
countries from 6 (Australia and Denmark) to 12 per cent (Finland). The selling motivation was 
somewhat more prevalent among those who provided themselves with medical cannabis than 
among those who provided others in Demark, Finland and the UK. In Australia and Belgium this
ratio was the other way, and there was equality between the groups in Germany. 
Illnesses, injuries or conditions to be treated with cannabis
Results presented in Table 3 show that medical growers were using cannabis for a wide variety of 
serious conditions. Three out of four of the respondents were suffering more than one condition. In 
Belgium, Finland and Germany fewer conditions were included in the list than in Australia, 
Denmark and the UK.
Insert table 3 about here












The most frequently reported conditions fell into two basic categories: physical illnesses like 
chronic pain, inflammation of the joints and migraine/headache on the one hand, and mental health 
problems like depression, anxiety and panic disorders on the other. The majority of medical 
growers were cultivating cannabis for these conditions. In the open response option insomnia and 
sleeping problems were mentioned relatively often in every country.
Multiple Sclerosis (MS), which is probably the condition for which medical cannabis is most widely 
recognised, officially, as being beneficial, was not often mentioned by medical growers in our 
samples. This probably just reflects the low prevalence of MS in the general population. On the 
other hand, MS has been recognized as a condition for legal access to Marinol® or Sativex® 
medication in most of the countries. It is also interesting to note that while HIV/AIDS patients have
been a visible patient group for medical cannabis in the USA (Mack & Joy, 2000; Geluardi, 2010; 
Reinarman et al., 2011), they were not very prevalent in our data. This is undoubtedly related to 
the fact that we recruited a wider population in our study than represented by the American 
medical marijuana patients.  Similarly, there was a relatively small proportion of respondents who 
reported use for cancer or nausea after chemotherapy. On the other hand, the proportion of 
respondents using cannabis as medicine for depression and other mood disorders was much 
higher in our data than among American medical marijuana patients (Reinarman et al., 2011).
Actually it was the most prevalent single health condition for which participants reported cannabis
use, and this held for each country.
There were some interesting differences between countries. First, figures in the Belgian sample 
seem to be lower than in other countries which may relate to how the question was structured in 
the Belgian questionnaire. Second, Scandinavian growers seemed to use cannabis for the 
treatment of ADHD more often than growers in other countries. Third, inflammation of joints as a 
reason for use was much more prevalent in Australia and the UK than in other countries, and same 
was true for the bowel problems as well as for anxiety and panic disorders. Fourth, a few 
respondents were using cannabis as medicine for dependence and withdrawal from other drugs, 












but in Finland, where the proportion was highest, several respondents informed in the open 
response option that they were using cannabis to manage alcohol problems. This may be seen 
reflecting the high prevalence of drinking problems in Finland.
Diagnoses and recommendations by medical doctor
Table 4 shows that a definite majority of the medical growers had a diagnosis from a doctor. This
confirms the observation from table 3 that many of them were suffering serious and medically 
established maladies. This is interesting, because there has been some suspicion whether most of 
those who define themselves as medical cannabis users are just justifying their recreational use by 
claiming for medical purposes (e.g. Wilkinson & D’Souza, 2014). Our data are based on self-
reporting and our knowledge about the patterns of use among our respondents is limited, but 
never-the-less, in these samples of medical growers across six countries three out of four reported 
having an authorized medical record for their conditions, and therefore a valid basis for their 
medical use of cannabis. 
Insert table 4 about here
Table 5 presents data on thos  who reported that they had been given a diagnosis. An important 
observation is that only a minority of the growers with a formal diagnosis had discussed the use of 
cannabis as medication with their doctors. Almost sixty per cent of the medical growers with a 
diagnosis reported that their doctor had not recommended cannabis and that they had not asked 
for it. Hence, in this sample of growers the use of cannabis in the treatment of diagnosed 
conditions was mostly a choice of the individual ‘patient’ rather than a clinical decision. This 
“practice of silence” was most prevalent in Finland where as many as 67 per cent of the 












respondents reported they had not taken up the issue of cannabis use when meeting their doctors. 
That might be due to the strict restrictive drug policy tradition in Finland (Kainulainen, 2009).
Insert table 5 about here
It is also interesting to note that approximately one in five respondents reported that their doctor 
had suggested the use of cannabis. In the context of limited legal access to medical cannabis 
treatment this is rather a high number. However, in 8 per cent of cases the doctor had refused to 
recommend cannabis even though the respondent had asked for it, and in 9 per cent the doctor 
had advised respondents against using cannabis. In sum, also nearly one in five of the medical 
growers with a formal diagnosis were treating their health problems with cannabis against their 
doctor’s advice.
Discussion
A central limitation of our study is connected to the general characteristics of internet-based 
research methods. Respondents for this study were not selected at random and hence, we don’t 
know the representativeness of the data. To minimize sampling limitations a wide variety of 
recruitment and promotion strategies were used (see xxxx, this volume). Moreover, in the case of 
researching hidden populations purposive, self-selected sampling procedures are a relevant and 
well established option, particularly since the basic population is unknown and could hardly be 
determined with representative surveys (Barratt et al., 2012). Even though our data cannot be said 
to represent all cannabis growers the relatively large number of respondents, 5,313 (2,346 of them 
medical growers) in these six countries, gives a reasonable basis for a descriptive analysis. In fact, 
this kind of procedure is common in cross-national comparisons (Strauss, 2009).












In general, the results from countries were quite similar, even though several national differences 
in details were found. However, these differences may be reflections of the different sampling 
strategies and resultant sample compositions (see xxxx, in this volume). This being the case it is 
reasonable to put more emphasis in commonalities and general features than disparities between 
the countries.
Our data from six countries show that growing cannabis for medical purposes (either for oneself or 
for others) is a widely spread motivation among small-scale cannabis growers. Over the years a 
number of researchers have produced typologies of cannabis cultivators and some of these 
classifications also note medical growers as a distinctive category of cultivators (Hough et al., 
2003; Potter, 2010; Potter, Bouchard, & Decorte, 2011). However, the place of medical growers 
within the range of cannabis cultivators has been seen as relatively minor. Results of this study 
indicate that the prevalence and social importance of medical growing might be more substantial in 
the cannabis growing community than has previously been recognised. 
Medical growers in our samples reported cultivating cannabis for wide variety of illnesses, injuries 
and conditions. As noted, the occurrence of different conditions was very different in our samples 
than in the samples of medical marijuana patients in the USA (Reinarman et al., 2011). The list of 
conditions in our samples seems to reflect more general public health problems, but less common 
diseases like AIDS or Multiple Sclerosis. The coverage of conditions in our samples also went far 
beyond the lists of officially approved conditions in these six countries.
The majority of medical growers in our study reported cultivating cannabis for serious conditions. 
Most of them also had a medical diagnosis. Hence, according to their self-reporting they were
suffering medically established maladies which they were treating through illicit activity. 
An alternative interpretation – especially regarding the high prevalence of medical motivation – is 
that there may be policy, law-enforcement and social desirability related reasons for citing medical 
reasons for cannabis growing and use by some respondents (Swift, Gates, & Dillon, 2005). Indeed, 












invoking medical purposes may also be seen as a neutralization of the stigma created by the illegal 
social position of cannabis. Growing for medical purposes may not be as subject to stigma as 
growing for pleasure and recreation. However, while there are studies suggesting that some users 
claiming medicinal use do not hesitate also to take advantage of the recreational potentialities of 
cannabis (Hakkarainen, Perälä & Metso, 2011b; Pedersen & Sanberg, 2013) other studies show 
that the use of cannabis is very different depending on whether it is for medical or recreational 
purposes (Dahl & Frank, 2011). In practice, as Reinarman et al. (2011, p. 134) argues, “it is not 
clear where a border line between medical and nonmedical marijuana or other drug use might be 
drawn nor how it might be effectively policed”.
While we know that respondents suffering medically established maladies use cannabis to self-
medicate these conditions, it was a shortcoming of our questionnaire that our data did not allow 
exploration of how this self-medication related to their use of pharmaceutical drugs for these 
conditions. Future research on medical cannabis should also include questions addressing the 
medical, rather than recreational, use of pharmaceutical drugs.
However, there is some evidence from other studies. A medical marijuana patient study in the USA 
suggested that around half of the patients are using marijuana as a substitute for prescription 
drugs (Reinarman et al., 2011). Even though cannabis might not be as effective an analgesic as 
the strongest pharmaceutical pain killers, it may be experienced as having fewer unpleasant side 
effects (see also Swift, Gates, & Dillon, 2005; Ware et al., 2005; Dahl & Frank, 2011). This 
argument of less unpleasant side-effects is also known in the cases of mental disorders (Dahl & 
Frank, 2011). Furthermore, using cannabis as a substitute for prescription medicines may also 
reflect a general mistrust towards pharmaceuticals. As it has recently turned out, the criticism and 
uncertainty towards the widespread use of pharmaceuticals has increased and, for example, it has 
been said that anti-depressants may not have much more than a placebo effect (Abraham, 2010; 
Horgan, 2011; Greenslit & Kaptchuk, 2012). Actually the medical cannabis movement as “an 
embodied health movement” challenges the existing medical knowledge and paradigmatic 












scientific methodology by emphasising intimate, first-hand knowledge of their own bodies and 
conditions (Penn, 2014). Hence, by this account, medical growers can be seen as not only 
distancing themselves from the illicit drug markets but also from the licit pharmaceutical medicines 
markets.
According to the self-reports of the growers in our samples, significant proportions were using 
cannabis for treatment of conditions, which research suggests cannabis use can actually 
exacerbate (e.g. depression and other mood disorders). Whilst acknowledging that there is some 
disagreement in the literature regarding the role of anxiolytic effects from cannabidiol (CBD) and 
the implications for treatment of such disorders (e.g. Walsh et al., 2013), there are questions about
the implications of these findings. Similar issues exist for using cannabis to treat pain related 
disorders although there is a growing scientific literature on the analgesic effectiveness of cannabis 
and cannabis products (Cooper, Comer, & Haney, 2013). In fact, from health policy and harm 
reduction perspectives, it can be seen as a worrying practice that many medical growers are using 
cannabis to treat serious medical conditions without medical advice and doctor’s guidance, or even 
against their doctor’s advice.
Even though our data do not prove or disprove the medical effectiveness of cannabis it raises 
questions about the relevance of these findings for policy and the status of cannabis as an 
approved treatment option for some of these conditions. The high prevalence of medical growing 
and self-medication in our samples indicates that there is a wider demand for a licit access for 
medical cannabis than available in these countries today. This would require changes as well in 
official policy (drug control and medical policies) as in present attitudes among clinicians. In any 
case, more research is needed. For example, the results of this study would suggest that further 
research on the therapeutic effects of cannabis should widen the scope of the studied conditions, 
particularly to the risks and benefits of anxiolytic and sedative use of cannabis. Investment in the 
development of safe – herbal and synthetic – preparations is also important.












Another interesting issue is the role of policy in the decisions that people make with regards to 
using an illicit drug for medical purposes. For example, to what extent do patients using cannabis 
without medical advice do so because they fear the risks of law enforcement and/or express the
denial by their doctor? This possibility complicates the issue of inadequate cannabis medication.
While using medical cannabis without a doctor’s recommendation could be risky for individual 
health, it might also be the result of difficulty obtaining medical cannabis products and the 
criminalization and stigma of cannabis use in general. Comparative research is needed to evaluate 
how users from countries or regions with a more liberal practice of medical cannabis use differ 
from those researched here.
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Table 1. Prevalence of medical growing in Australia, Belgium, Denmark, Finland, Germany and the UK, %
Growing for medical reasons Australia Belgium Denmark Finland Germany UK Total
 (N=491) (N=1065) (N=813) (N=1179) (N=1347) (N=418) (N=5313)
Provide others 19.6 7.8 17.5 17.0 12.3 18.2 14.4
Provide oneself 53.6 19.2 42.6 52.8 34.8 52.4 40.0
Other reasons* 42.4 77.6 51.5 43.7 58.8 42.3 55.3
I don't want to answer 0 0.2 0 0 0.1 0 0.1
*Not growing for medical purposes
Countries












Table 2. Mean and median age of medical growers Australia, Belgium, Denmark, Finland, Germany and the 
UK
Age Australia Belgium Denmark Finland Germany UK Total
(N=283) (N=237) (N=393) (N=664) (N=533) (N=236) (N=2346) F-test p-value
Mean (yrs) 39.0 32.3 33.1 28.4 30.9 35.8 32.2 47.125 <0.001
Median (yrs) 38 29 30 26.5 28 36 29
Range (yrs) 18-71 18-71 18-69 18-61 18-74 18-63 18-74
Countries












Table 3. Illnesses, injuries or conditions for which cannabis was used as medicine in Australia, Belgium, 
Denmark, Finland, Germany and the UK, %  












Conditions Australia Belgium Denmark Finland Germany UK Total
 (N=208) (N=205) (N=346) (N=623) (N=469) (N=219) (N=2070)
Depression/other mood disorders 46.6 18.0 44.8 40.4 48.8 52.5 42.8
Chronic pain (e.g. fibromyalgia) 31.7 15.6 38.7 27.8 44.1 31.1 32.9
Anxiety or panic disorders 45.2 - 24.6 26.8 - 36.1 30.4 *
Migraines and headaches 24.0 - 33.5 18.0 - 26.5 24.1 *
ADHD 11.1 - 21.1 16.5 - 6.8 15.3 *
Bowel problems 16.8 - 11.0 - - 16.4 14.1 *
Inflammation of the joints (arthritis) 31.3 7.8 15.9 6.1 9.6 29.7 13.7
Post Traumatic Stress Disorder (PTSD) 14.9 - 10.1 - - 9.1 11.1 *
Asthma 7.2 2.9 9.5 11.1 13.6 8.2 9.9
Dependence and withdrawal from other drugs 7.7 2.0 6.6 10.8 5.8 6.4 7.3
Autism and Asperger’s syndrome 5.3 - 5.5 - - 5.5 5.4 *
Hypertension 6.7 0.0 4.0 4.2 7.2 7.8 5.1
Anorexia 3.8 1.0 4.0 7.5 - 2.7 4.8 *
Cancer 6.3 - 8.7 1.3 - 4.1 4.3 *
Schizophrenia 1.4 - 5.5 - - 0.5 3.0 *
Eye disease (glaucoma) 3.4 1.0 3.2 1.4 5.1 2.3 2.8
Hepatitis 4.8 - 1.4 - - 1.8 2.5 *
Nausea e.g. after chemotherapy 1.9 0.5 6.1 0.3 2.3 2.3 2.1
Multiple Sclerosis 0.0 1.5 3.8 1.0 3.2 2.3 2.0
Tourette Syndrome 0.5 1.0 2.9 - 1.5 0.5 1.5 *
HIV/AIDS 0.5 - 1.4 - - 0.9 1.0 *
Parkinson’s disease 0.5 0.5 1.4 0.0 1.1 0.0 0.6
Other 35.6 36.1 32.1 12.2 36.5 40.2 28.7
I don't know 0.0 - 0.6 4.0 0.6 0.5 1.7 *
I don't want to answer 1.0 - 0.3 1.1 4.9 1.4 1.9 *
- Information is lacking, not included as a category
* Total N is the sum of the N's of countries with the information of disease at issue, i.e. less than 2070
Countries












Table 4. Diagnosis of illnesses, injuries or conditions among medical growers in Australia, Belgium, 
Denmark, Finland, Germany and the UK, in %
Diagnoses Australia Belgium Denmark Finland Germany UK Total
(N=195) (N=179) (N=100) (N=604) (N=443) (N=209) (N=1730)
Have a diagnosis 89.7 64.8 88.0 69.0 77.0 90.4 76.6
Not diagnosed by a doctor 9.7 35.2 12.0 22.0 19.4 9.6 19.2
I don't know 0.0 0.0 0.0 6.0 1.1 0.0 2.4
I don't want to answer 0.5 0.0 0.0 3.0 2.5 0.0 1.7
Countries












Table 5. Doctor’s recommendations on medical cannabis use as reported by medical growers having a 
diagnosis in Australia, Belgium, Denmark, Finland, Germany and the UK, % 
Doctor’s recommendation Australia Belgium Denmark Finland Germany UK Total
(N=175) (N=102) (N=87) (N=415) (N=341) (N=187) (N=1307)
Doctor not recommended and 
person not asked for
50,3 - 54,0 67,5 - 49,7 58,8 *
Doctor suggested cannabis 23,4 25,5 13,8 8,9 22,6 15,5 17,0
Doctor advised to avoid using cannabis 6,9 - 9,2 10,4 - 7,5 8,9 *
Doctor refused to recommend 
even though asked for it
5,7 - 3,4 9,2 - 10,7 8,2 *
Doctor is aware of my cannabis use and does 
not object**
9,1 - 4,6 - - 6,4 7,1 *
Other 3,4 - 12,6 - - 8,0 7,1 *
I don't know 0,6 - 1,1 3,1 4,7 0,5 2,7 *
I don't want to answer 0,6 - 1,1 1,0 5,0 1,6 2,2 *
- not asked
* Total N is the sum of the N's of countries with the information at issue, i.e. less than 1307
** This category was created based on recording the other text responses
Countries













 Growing cannabis for medical purposes was a widespread motivation among the small-scale 
cannabis growers in six countries.
 The majority of medical growers reported using cannabis for serious illnesses, injuries or 
conditions. 
 According this self-reporting data most of medical growers did have a formal diagnosis of their 
medical condition. 
 In most cases this self-medication was not taken up in the meetings with their doctors.
